PE20030822A1 - FORMA CRISTALINA DE 6-[(2,2-DIFENILETIL)AMINO]-9-(N-ETIL-ß-D-RIBOFURANOSIL-URONAMIDA)-N-(2-{N'-[1-(2-PIRIDIL)-4-PIPERIDIL]UREIDO}ETIL)-9H-PURIN-2-CARBOXAMIDA - Google Patents

FORMA CRISTALINA DE 6-[(2,2-DIFENILETIL)AMINO]-9-(N-ETIL-ß-D-RIBOFURANOSIL-URONAMIDA)-N-(2-{N'-[1-(2-PIRIDIL)-4-PIPERIDIL]UREIDO}ETIL)-9H-PURIN-2-CARBOXAMIDA

Info

Publication number
PE20030822A1
PE20030822A1 PE2002001155A PE2002001155A PE20030822A1 PE 20030822 A1 PE20030822 A1 PE 20030822A1 PE 2002001155 A PE2002001155 A PE 2002001155A PE 2002001155 A PE2002001155 A PE 2002001155A PE 20030822 A1 PE20030822 A1 PE 20030822A1
Authority
PE
Peru
Prior art keywords
ethyl
uronamide
ureide
diphenylethyl
ribofuranosyl
Prior art date
Application number
PE2002001155A
Other languages
English (en)
Inventor
Julian Duncan Smith
Terence Vernon Silk
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030822A1 publication Critical patent/PE20030822A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)

Abstract

SE REFIERE A FORMA CRISTALINA DE 6-[(2,2-DIFENILETIL)AMINO]-9-(N-ETIL-ß-D-RIBOFURANOSIL-URONAMIDA)-N-(2-{N'-[1-(2-PIRIDIL)-4-PIPERIDIL]UREIDO}ETIL)-9H-PURIN-2-CARBOXAMIDA CARACTERIZADO POR SU ESPECTRO DE INFRARROJO, PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION QUE COMPRENDE DISOLVER EL COMPUESTO AMORFO EN UN DISOLVENTE ORGANICO (2-BUTANONA, ACETATO DE ETILO, ACETONITRILO, ACETATO DE ISOPROPILO, ISOPROPANOL, ACETATO DE METILO, ENTRE OTROS) QUE CONTIENE 2%p/p DE AGUA DISUELTA; CALENTAR LA SOLUCION OBTENIDA A UNA TEMPERATURA DE 50°C A 80°C, HASTA QUE SE PRODUZCA LA CRISTALIZACION. EL CONTENIDO DE AGUA DEL DISOLVENTE ORGANICO ES DE 2%. EL COMPUESTO ES AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y PUEDE SER UTIL COMO ANTIINFLAMATORIO PARA EL TRATAMIENTO DE UNA ENFERMEDAD RESPIRATORIA COMO SINDROME DE INSUFICIENCIA RESPIRATOIRA EN ADULTOS, BRONQUITIS, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, FIBROSIS QUISTICA, ASMA, ENFISEMA
PE2002001155A 2001-12-06 2002-12-02 FORMA CRISTALINA DE 6-[(2,2-DIFENILETIL)AMINO]-9-(N-ETIL-ß-D-RIBOFURANOSIL-URONAMIDA)-N-(2-{N'-[1-(2-PIRIDIL)-4-PIPERIDIL]UREIDO}ETIL)-9H-PURIN-2-CARBOXAMIDA PE20030822A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129273.9A GB0129273D0 (en) 2001-12-06 2001-12-06 Crystalline drug form

Publications (1)

Publication Number Publication Date
PE20030822A1 true PE20030822A1 (es) 2003-10-04

Family

ID=9927165

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2002001154A PE20030722A1 (es) 2001-12-06 2002-12-02 Combinacion de una forma de farmaco cristalina y una sal de tiotropio
PE2002001155A PE20030822A1 (es) 2001-12-06 2002-12-02 FORMA CRISTALINA DE 6-[(2,2-DIFENILETIL)AMINO]-9-(N-ETIL-ß-D-RIBOFURANOSIL-URONAMIDA)-N-(2-{N'-[1-(2-PIRIDIL)-4-PIPERIDIL]UREIDO}ETIL)-9H-PURIN-2-CARBOXAMIDA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2002001154A PE20030722A1 (es) 2001-12-06 2002-12-02 Combinacion de una forma de farmaco cristalina y una sal de tiotropio

Country Status (41)

Country Link
US (3) US20030144243A1 (es)
EP (1) EP1456219B1 (es)
JP (1) JP4184279B2 (es)
KR (1) KR100554333B1 (es)
CN (1) CN100381454C (es)
AP (1) AP2004003056A0 (es)
AR (2) AR038547A1 (es)
AT (1) ATE364615T1 (es)
AU (2) AU2002351056A1 (es)
BR (1) BR0214747A (es)
CA (1) CA2468847C (es)
CY (1) CY1106822T1 (es)
DE (1) DE60220713T2 (es)
DK (1) DK1456219T3 (es)
EA (1) EA006857B1 (es)
EC (1) ECSP045141A (es)
ES (1) ES2286303T3 (es)
GB (1) GB0129273D0 (es)
GT (2) GT200200256A (es)
HK (1) HK1071143A1 (es)
HN (1) HN2002000352A (es)
HR (1) HRP20040516A2 (es)
HU (1) HUP0700046A2 (es)
IL (2) IL162101A0 (es)
IS (1) IS7279A (es)
MA (1) MA27151A1 (es)
MX (1) MXPA04005505A (es)
NO (1) NO20042837L (es)
NZ (1) NZ533053A (es)
OA (1) OA12737A (es)
PA (2) PA8560501A1 (es)
PE (2) PE20030722A1 (es)
PL (1) PL370971A1 (es)
PT (1) PT1456219E (es)
RS (1) RS49504A (es)
SV (1) SV2004001425A (es)
TN (1) TNSN04103A1 (es)
TW (2) TW200301129A (es)
UY (1) UY27568A1 (es)
WO (2) WO2003048180A1 (es)
ZA (1) ZA200403967B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225089A1 (en) * 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
DE10345065A1 (de) * 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2021084791A1 (ja) * 2019-10-28 2021-05-06 有限会社イムノ アデノシンａ２ａ受容体を標的とする組成物
CN115400140B (zh) * 2022-01-27 2024-02-20 宁波熙健医药科技有限公司 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
WO2001020089A1 (fr) 1999-09-10 2001-03-22 Maeda Corporation Structure de beton et procede de construction
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
JP2004505526A (ja) 2000-07-26 2004-02-19 スイスコム　モービル　アーゲー 移動体通信網の基地局を設置し、基地局と移動体通信網とを接続する方法
MXPA03010787A (es) * 2001-05-25 2004-03-02 Pfizer Un agonista del receptor a2a de adenosina en combinacion con un agente anticolinergico para el tratamiento de enfermedades obstructivas de las vias aereas.

Also Published As

Publication number Publication date
HK1071143A1 (en) 2005-07-08
KR20050058272A (ko) 2005-06-16
EP1456219B1 (en) 2007-06-13
AR038547A1 (es) 2005-01-19
JP4184279B2 (ja) 2008-11-19
CN1599745A (zh) 2005-03-23
GT200200256A (es) 2003-07-03
AP2004003056A0 (en) 2004-06-30
PL370971A1 (en) 2005-06-13
PE20030722A1 (es) 2003-08-29
US20030144243A1 (en) 2003-07-31
ECSP045141A (es) 2004-07-23
SV2004001425A (es) 2004-05-07
WO2003047597A1 (en) 2003-06-12
IS7279A (is) 2004-05-21
PT1456219E (pt) 2007-08-03
IL162101A0 (en) 2005-11-20
OA12737A (en) 2006-06-29
DE60220713T2 (de) 2008-03-06
US7022727B2 (en) 2006-04-04
AR037633A1 (es) 2004-11-17
AU2002351056A1 (en) 2003-06-17
HUP0700046A2 (en) 2007-03-28
US6852746B2 (en) 2005-02-08
JP2005513043A (ja) 2005-05-12
CN100381454C (zh) 2008-04-16
BR0214747A (pt) 2004-09-14
AU2002347509B2 (en) 2008-09-18
RS49504A (en) 2006-10-27
UY27568A1 (es) 2003-07-31
PA8560501A1 (es) 2003-09-17
HN2002000352A (es) 2003-07-23
ES2286303T3 (es) 2007-12-01
DK1456219T3 (da) 2007-09-24
ZA200403967B (en) 2006-05-31
US20050085437A1 (en) 2005-04-21
AU2002347509A1 (en) 2003-06-17
CA2468847C (en) 2008-10-21
TW200301130A (en) 2003-07-01
WO2003048180A1 (en) 2003-06-12
MXPA04005505A (es) 2005-06-03
GT200200257A (es) 2003-07-11
KR100554333B1 (ko) 2006-02-22
CA2468847A1 (en) 2003-06-12
CY1106822T1 (el) 2012-05-23
NO20042837L (no) 2004-08-24
EA006857B1 (ru) 2006-04-28
DE60220713D1 (de) 2007-07-26
TW200301129A (en) 2003-07-01
IL162101A (en) 2010-04-29
MA27151A1 (fr) 2005-01-03
TNSN04103A1 (fr) 2006-06-01
ATE364615T1 (de) 2007-07-15
EP1456219A1 (en) 2004-09-15
HRP20040516A2 (en) 2004-10-31
GB0129273D0 (en) 2002-01-23
US20030158145A1 (en) 2003-08-21
PA8560301A1 (es) 2003-11-12
EA200400638A1 (ru) 2004-10-28
NZ533053A (en) 2006-09-29

Similar Documents

Publication Publication Date Title
ES2343421T3 (es) Derivados de purina como agonistas de los receptores a1 de adenosina y metodos de uso de los mismos.
ES2685591T3 (es) Nucleósidos, nucleótidos sustituidos y análogos de los mismos
ES2212547T3 (es) Nuevas formas de preparados galenicas del principio activo meloxicam.
JP3602445B2 (ja) アデニン誘導体
ES2469916T3 (es) Sal de tipo tosilato de un derivado de 5-pirazolil-2-piridona, útil en el tratamiento de la epoc
ES2304352T3 (es) Compuestos farmacologicamente activos con dos principios activos unidos covalentemente (bloqueante de los canales de sodio/agonista del receptor p2y2) para el tratamiento de superficies mucosas.
JP2009534336A (ja) アデノシンａ２ａ受容体アゴニストとしての２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオールの使用
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
PE20030822A1 (es) FORMA CRISTALINA DE 6-[(2,2-DIFENILETIL)AMINO]-9-(N-ETIL-ß-D-RIBOFURANOSIL-URONAMIDA)-N-(2-{N'-[1-(2-PIRIDIL)-4-PIPERIDIL]UREIDO}ETIL)-9H-PURIN-2-CARBOXAMIDA
NO20065757L (no) Purinderivater
JP2004501930A5 (es)
PT2013211E (pt) Derivados de purina para utilização como agonistas de receptores a2a de adenosina
JP2019524702A5 (es)
BRPI0710484A2 (pt) compostos orgánicos
CN108003153A (zh) 含氮五元杂环并喹啉类化合物及其盐、制法、药物组合物和用途
JP5417558B2 (ja) 置換８−［６−アミノ−３−ピリジル］キサンチン類
BRPI0612628A2 (pt) 1-(2-amina-3-(alquil substituÍdo)-3h-benzimidazolil)metil]-3-substituÍdo-1 ,3-diidro-benzoimidazol-2-onas com atividade sobre vÍrus sincicial respiratàrio
Zupančič et al. Physical characterization of pantoprazole sodium hydrates
CA3009510A1 (en) Phenylamino-1,3,5- triazine derivatives and use thereof as cftr regulators
JP2005529084A5 (es)
Veverka et al. Imatinib mesylate cocrystals: synthesis, screening, and preliminary characterization
CN105820093A (zh) 一种n-苄基-5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-乙氧基苯甲酰胺新化合物、制备方法及用途
ES2901157T3 (es) Nuevo cristal de compuesto de piperazina
CN100480255C (zh) A1腺苷受体的部分和完全激动剂
CN105820090A (zh) 一种5-[3-（2,5-二乙氧基-4-甲磺酰基-苄基）-脲基]-2-乙氧基-n-（3-甲氧基-苯基）-苯甲酰胺新化合物、制备方法及用途

Legal Events

Date Code Title Description
FD Application declared void or lapsed